Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.
Wang
Shudong
S
Cyclacel Limited, Dundee DD15JJ, Scotland, UK.
Griffiths
Gary
G
Midgley
Carol A
CA
Barnett
Anna L
AL
Cooper
Michael
M
Grabarek
Joanna
J
Ingram
Laura
L
Jackson
Wayne
W
Kontopidis
George
G
McClue
Steven J
SJ
McInnes
Campbell
C
McLachlan
Janice
J
Meades
Christopher
C
Mezna
Mokdad
M
Stuart
Iain
I
Thomas
Mark P
MP
Zheleva
Daniella I
DI
Lane
David P
DP
Jackson
Robert C
RC
Glover
David M
DM
Blake
David G
DG
Fischer
Peter M
PM
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D017209:Apoptosis; D001665:Binding Sites; D045744:Cell Line, Tumor; D003198:Computer Simulation; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D051379:Mice; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000627:therapeutic use; D011743:Pyrimidines / Q000737:chemistry* / Q000627:therapeutic use; D014158:Transcription, Genetic / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D016159:Tumor Suppressor Protein p53; D018844:Cyclin-Dependent Kinases